Related Experiment Video

Updated: Jun 30, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Staging of Fabry cardiomyopathy in clinical practice: an algorithm proposal

Inês Fortuna1, Janete Santos1, Raquel Machado1

  • 1Faculty of Medicine, University of Porto, Portugal.

International Journal of Cardiology. Heart & Vasculature
|February 20, 2026
PubMed

Insights

A new staging system effectively classifies Fabry disease (FD) cardiomyopathy stages, with most patients identified in earlier, non-hypertrophic phases. This approach aids clinical application for FD cardiac assessment.

Area of Science:

  • Cardiology
  • Genetics
  • Medical Imaging

Background:

  • Fabry disease (FD) is a genetic disorder characterized by hypertrophic cardiomyopathy.
  • Early diagnosis and staging are crucial for managing FD, guiding treatment with enzyme replacement or chaperone therapies.
  • A recent clinical staging proposal for Fabry cardiomyopathy categorizes patients into five stages (0A, 0B, IA, IB, II, III) based on cardiac imaging findings like hypertrophy and fibrosis.

Purpose of the Study:

  • To evaluate the applicability of the Meucci et al. 2024 clinical staging proposal for Fabry cardiomyopathy in a cohort of FD patients.
  • To assess the utility of cardiac imaging evaluations, including hypertrophy and fibrosis characterization, within the proposed staging framework.

Main Methods:

  • A retrospective observational study involving patients diagnosed with Fabry disease.
  • Application of a hierarchical flowchart staging system based on left ventricular ejection fraction (LVEF), late gadolinium enhancement (LGE), left ventricular (LV) wall thickness, and other cardiac findings.
  • Full algorithm application to 44 out of 53 FD patients due to the necessity of cardiac magnetic resonance and echocardiogram parameters.

Main Results:

  • The staging system successfully classified different stages of Fabry disease cardiomyopathy.
  • The majority of patients (29.5%) were classified in the non-hypertrophic stage 0.
  • Stage I (hypertrophic) included 27.2% of patients, stage II (hypertrophic fibrotic) included 29.5%, and stage III (advanced fibrosis/impaired function) included 13.6%.

Conclusions:

  • The proposed staging scheme effectively classifies Fabry disease cardiomyopathy.
  • Most patients were identified in early disease stages, potentially due to familial screening protocols.
  • The stepwise algorithm facilitates clinical application but requires validation in larger, prospective studies.
Abstract

Keywords:
Classification algorithmFabry diseaseHypertrophic cardiomyopathyStaging

More Related Videos

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures10:01

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 12, 2018

In Silico Clinical Trials for Cardiovascular Disease09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...